The Globe and Mail spoke with our CEO, Tamer Mohamed, and CTO, Simon Beyer, to discuss the history of Aspect, our microfluidic 3D bioprinting technology, and how we're applying it to develop bioprinted therapeutics.
“What we’re doing is using our printing technology to create living tissue to replace damaged biological function inside of the body. This is a frontier focus in terms of medical innovation, where we’re trying to turn sci-fi into reality and create living tissue that could really change patient care.” - Tamer Mohamed, CEO, Aspect Biosystems
Read the article here.
Source: The article was originally published by The Globe and Mail on October 20, 2021.Back to all